Scientific Research

Scientific Research

Clinically proven pain control with a superior safety profile.

MEPTID® (Meptazinol 100 mg solution for injection) is a centrally acting opioid analgesic that delivers rapid and effective pain relief while minimizing the risks commonly associated with conventional opioids.

By acting as a partial agonist at the μ₁ receptor and a μ₂ receptor antagonist, MEPTID® achieves strong analgesia with minimal respiratory and cardiac depression.

Its short duration of action, rapid onset, and non-addictive nature make it an ideal solution for acute, surgical, labor pain and emergency pain management.

Pharmacokinetic Profile

After intravenous injection, MEPTID® begins acting almost immediately, while intramuscular administration produces an effect within approximately 15 minutes.

Its analgesic effect lasts around 2 to 2.5 hours when given intravenously and 3 to 4 hours following intramuscular injection.

MEPTID® has a short elimination half-life of about 2 hours, which allows it to be administered in carefully controlled intervals.

It undergoes hepatic metabolism, forming inactive metabolites, and is excreted primarily through the renal pathway.

The drug exhibits low plasma protein binding (27%), enabling a quick onset of action and predictable offset.

This low binding characteristic ensures that MEPTID® acts rapidly and is cleared efficiently, reducing the risk of accumulation and allowing flexible dosing based on individual patient needs.

These properties make MEPTID® a short-acting, reversible, and safe analgesic option for clinical use.

Pharmacological Characteristics

MEPTID®’s pharmacological behavior is distinct from that of conventional opioids, offering an optimal balance between efficacy and safety.

Partial μ₁ receptor agonism: Produces potent analgesic effects with minimal sedation.
μ₂ receptor antagonism: Prevents respiratory depression, bradycardia, and euphoria.
Low intrinsic activity: Results in a much lower risk of dependency or abuse potential.
Short duration of action: Allows precise titration during procedures or recovery phases.

These characteristics provide clinicians with greater control over analgesia, especially in patients requiring short-term opioid management where safety and recovery speed are essential.

MEPTID® combines the desired analgesic properties of an opioid with the safety of a non-controlled drug classification

Clinical Research and Evidence

Clinical

Research & Evidence

Integrated Clinical Interpretation

Across these peer-reviewed investigations, MEPTID® consistently showed that it:

Achieves rapid and substantial pain reduction equivalent to conventional opioids.
Produces markedly less sedation and cognitive impairment.
Maintains normal ventilatory and cardiovascular parameters.
Offers predictable onset and offset, supporting procedural use.
Is non-addictive and non-controlled in several regulatory regions (e.g., BfArM Germany, UK MHRA).